Australia's most trusted
source of pharma news
Posted 3 March 2026 PM
Eli Lilly is pushing the case for wider government reimbursement of obesity medications with a new report from GlobalData indicating obesity and overweight is costing Australia $45 billion each year.
The pharma giant is keen to extend funding for weight loss drugs beyond people with obesity and comorbidities to a wider population, banking on improving perception of its obesity drug Mounjaro. Last November the PBAC gave a recommendation to Novo Nordisk for Wegovy, for people with established cardiovascular disease with obesity, after failing twice to recommend the drug for obesity alone.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.